secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001159036-23-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q1 revenue up 38% to $162M; GAAP EPS $0.29; reiterates 2023 guidance
-----------------------------------------------------------------------------

- Revenue of $162.1M (+38% YoY); royalty revenue $99.6M (+43% YoY).
- GAAP diluted EPS $0.29; non-GAAP diluted EPS $0.47 (flat YoY).
- Q1 net income $39.6M vs $60.1M in Q1 2022; EBITDA $74.3M.
- Reiterates 2023 guidance: total revenue $815-845M, non-GAAP EPS $2.50-$2.65.
- Repurchased 4.2M shares for $150M in Q1; $275.6M cash end of quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000037/0001159036-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000037/halo-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001159036-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer